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Abstract
Objective—The International Mission on Prognosis and Analysis of Clinical Trials (IMPACT)
and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models predict
outcome after traumatic brain injury (TBI) but have not been compared in large datasets. The
objective of this is study is to validate externally and compare the IMPACT and CRASH
prognostic models for prediction of outcome after moderate or severe TBI.
Design—External validation study.
Patients—We considered 5 new datasets with a total of 9036 patients, comprising three
randomized trials and two observational series, containing prospectively collected individual TBI
patient data.
Measurements—Outcomes were mortality and unfavourable outcome, based on the Glasgow
Outcome Score (GOS) at six months after injury. To assess performance, we studied the
discrimination of the models (by AUCs), and calibration (by comparison of the mean observed to
predicted outcomes and calibration slopes).
Main Results—The highest discrimination was found in the TARN trauma registry (AUCs
between 0.83 and 0.87), and the lowest discrimination in the Pharmos trial (AUCs between 0.65
and 0.71). Although differences in predictor effects between development and validation
populations were found (calibration slopes varying between 0.58 and 1.53), the differences in
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discrimination were largely explained by differences in case-mix in the validation studies.
Calibration was good, the fraction of observed outcomes generally agreed well with the mean
predicted outcome. No meaningful differences were noted in performance between the IMPACT
and CRASH models. More complex models discriminated slightly better than simpler variants.
Conclusions—Since both the IMPACT and the CRASH prognostic models show good
generalizability to more recent data, they are valid instruments to quantify prognosis in TBI.
Keywords
external validation; outcome; prediction models; traumatic brain injury
INTRODUCTION
Traumatic brain injury (TBI) remains the main cause of death and disability in young adults
worldwide (1) (2). It is a heterogeneous disease with respect to cause, pathology, severity
and prognosis. This causes considerable uncertainty in the expected outcome of individual
patients. Prognostic models can be used to combine different characteristics of an individual
patient to predict outcome. Reliable outcome predictions can be used to provide realistic
information to relatives, for more efficient design and analysis of clinical trials in TBI and
can provide a reference for assessing the quality of health care delivery (3).
Many prognostic models for TBI have been developed in the past decades, with varying
methodological quality (4) (5). Only two sets of prognostic models were developed on large
datasets and according to the latest methodological insights. These are the models developed
on the International Mission on Prognosis and Analysis of Clinical trials in Traumatic brain
injury database (IMPACT models) and the Corticosteroid Randomisation After Significant
Head Injury trial data (CRASH models) (6) (7).
Prognostic models are mathematical models developed from specific populations. External
validation is necessary to determine the ability of a model to reliably predict outcome in
populations, different from the development setting. Both the IMPACT models and the
CRASH models have been externally validated previously, using each other’s development
datasets, indicating satisfactory generalizability. Nevertheless, a broader validation and
comparison of these models has not yet been performed (8).
In this study we aimed to validate externally the IMPACT and CRASH prognostic models in
five relatively recent datasets and to compare these different models to predict mortality and
unfavourable outcome.
MATERIALS AND METHODS
Models
Details of the development of the prognostic models were reported previously (6) (7). In
summary, the IMPACT models were developed on a dataset with 8509 patients from eleven
studies (i.e., three surveys and eight randomized controlled trials) on moderate and severe
TBI (9). Three different models were developed for the prediction of mortality and
unfavourable outcome (Death, Vegetative State, Severe Disability), based on the
dichotomized Glasgow Outcome Score (GOS) at six months after injury. These included the
Core Model, the Extended Model and the Lab Model (Table 1). External validation was
performed in patients with moderate to severe TBI enrolled in the CRASH trial dataset
(n=6681).
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The CRASH models were developed on the CRASH trial dataset (n=10008) with patients
who sustained mild, moderate and severe TBI, mostly from low and middle-income
countries (n=7526, 75%) (10) (11). Two different models were developed for both the
prediction of mortality at two weeks after injury and unfavourable outcome at six months,
using the dichotomized GOS. The models included the Basic Model and the more extensive
CT Model (Table 1). The IMPACT dataset (n=8509) was used for external validation.
Because the original CRASH models were developed for prediction of outcome in all TBI
severity groups (including mild: GCS scores 13–15) and not all variables of the CRASH
models were available in the validation datasets (see below), we refitted an adapted version
of the CRASH models in a selection of 6681 patients with moderate to severe TBI (GCS ≤
12), ≥ 14 years of age and with available outcome data. In the refitted models, the total GCS
score was replaced by the GCS motor score. Further, the Marshall CT classification and the
presence of traumatic subarachnoid hemorrhage were included in the refitted CRASH CT
model, instead of the original CT variables (Table 1). New regression coefficients and
intercepts were obtained for both the CRASH Basic and the CRASH CT models for
prediction of mortality at two weeks and unfavourable outcome at six months (Supplemental
Digital Content, Appendix 2).
Datasets for external validation
NABIS Hypothermia—The NABIS Hypothermia study (1994–1998) was a multicenter
randomized trial performed in the United States investigating the effect of hypothermia in
severe TBI (12). The primary outcome was the GOS at six months after injury. The trial was
terminated after inclusion of 392 of the planned 500 patients, because an interim analysis
showed that the probability of detecting a treatment effect after expansion to 500 included
patients was smaller than 1%. For the validation, we excluded patients younger than 14
years of age or with missing outcome (n=3), resulting in a dataset of 385 patients.
Cerestat—Cerestat is an unpublished multicenter randomized controlled trial in a
combined group of North American and European centers investigating the effect of
Aptiganel HCl, a non-competitive NMDA (N-methyl-D-aspartate) receptor antagonist, in
severe TBI (GCS ≤ 8). In 1996 and 1997, 547 patients were enrolled in the trial. An interim
analysis performed at the end of 1997 resulted in the decision that continuation of the trial
was unjustified (13). No benefit of the study drug was found in TBI patients. As outcome
was missing in 30 patients, a total of 517 were available for validation.
APOE—This single-center observational cohort study (1996–1999, Glasgow, Scotland)
investigated the hypothesis that the possession of the APOE e4 allele is associated with a
poor outcome after TBI (14). In total, 1094 patients were enrolled, of whom 513 (54%) had
a mild TBI (GCS 13–15). The outcome was the GOS at six months after injury. No overall
association between the APOE genotype and outcome was found. To be consistent, we
excluded patients with GCS > 12 and age < 14, resulting in a dataset with 404 patients.
Pharmos—The Pharmos Dexanabinol study (2001–2004) was a randomized multicenter,
placebo-controlled, phase III trial investigating the safety and efficacy of dexanabinol in
patients with severe TBI carried out in Europe, Israel, Australia and the United States (15).
The study enrolled 861 subjects. The study publication reported dexanabinol to be safe but
not efficacious in the treatment of TBI. Because of missing 6-month outcome, five patients
were excluded from our analyses, resulting in a dataset of 856 patients.
TARN—The Trauma Audit and Registry Network (TARN) is a hospital-based trauma
registry in England and Wales including all patients with trauma resulting in immediate
Roozenbeek et al. Page 3
Crit Care Med. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
admission to hospital for three days or longer or death. The outcome measure is in-hospital
mortality. For the validation, we selected patients ≥ 14 years of age enrolled between 2001
and 2009 with moderate or severe TBI (GCS ≤ 12), defined as having an Abbreviated Injury
Scale Head of 3 or higher, which was not resulting from scalp laceration, avulsion or
penetrating brain injury, with outcome data available, resulting in a dataset of 6874 patients.
Data analysis
The IMPACT and CRASH models (Table 1) were validated in these five validation datasets,
all originated from high income countries (Europe, North-America and Australia). Some
models could not be applied to all datasets, because not all required predictor or outcome
variables were available. Coding of the different predictors in the validation datasets was
according to the IMPACT predictor coding as described previously (9). Data on age and
GCS motor score, pupillary reactivity, hypoxia and hypotension were available for all
validation datasets. However, in TARN data on pupils were only collected in the latter years
of inclusion, resulting in a large number of missing values with only 693 pupils available for
6874 patients, 10%. Missing values occurred for several other predictors, mainly because
some predictors were not collected in all studies. Table 2 includes information on the total
number of patients included in the dataset and on the availability of the parameters of
interest in these datasets. In TARN, some CT data were available (EDH and tSAH), but the
Marshall CT Classification was not scored directly, and therefore derived with an algorithm
using the AIS as a basis (16). Missing values were assumed to be missing at random and
were statistically imputed. For the imputation procedure, the aregImpute function in R
software was used (17).
To quantify differences in the distribution of patient characteristics between the different
studies, we calculated a summary measure of heterogeneity. This measure is defined as the
standard deviation (SD) of the linear predictor (LP) values of a logistic regression model,
with mortality as the outcome variable and age, GCS motor score and pupillary reactivity as
predictor variables. The LP value is directly related to the predicted probability of mortality.
In a relatively homogeneous population the predicted probabilities - and thus LP values - for
all patients will be relatively close together, with a small SD. In a more heterogeneous
population, the LPs will be more dispersed and the SD is larger.
Model performance
We assessed the performance of the models in the new datasets in terms of discrimination
and calibration. Discrimination describes how well a model distinguishes between patients
with and without the outcome of interest. Calibration indicates how closely predicted
outcomes match observed outcomes.
To assess discrimination, we calculated the area under the receiver operating characteristic
curve (AUC). An AUC of 1 implies perfect discrimination, whereas an AUC of 0.5 implies
that a model’s discrimination is no better than chance. Discrimination in an external
validation setting can be influenced in several ways. The predictor effects in the model can
be different, resulting in an invalid model. But differences in the distribution of patient
characteristics (“case-mix”) between the development and validation data may also
influence discriminative power of the model. In a population with a prognostically
homogeneous case-mix, it will be more difficult to distinguish between patients with a good
or poor outcome with, than in a heterogeneous population. For example, in an observational
study with broad inclusion criteria, discrimination of a model will be better than in a strictly
selected trial population.
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To take these effects into account, we calculated two recently proposed benchmark values
for the AUC: the case-mix-corrected and the refitted AUC (18). The case-mix-corrected
AUC indicates the discriminative power of a model, under the assumption that the predictor
effects are fully correct for the validation population. It was calculated by simulating new
outcome values for all patients in the validation dataset, based on the predicted risks for each
patient calculated by the prognostic model. We performed 1000 repetitions to obtain stable
estimates. The refitted AUC indicates the discriminative power that can be obtained by
refitting the model in the validation dataset, resulting in new, optimal predictor effects. This
resulted in an upper bound for the discriminative power, which would be found if the
predictor effects in the validation dataset were exactly the same as in the development
population.
To assess calibration, we plotted observed versus predicted outcome. We assessed
calibration-in-the-large by fitting a logistic regression model with the model predictions as
an offset variable. The intercept indicates whether predictions are systematically too low or
too high, and should ideally be zero. The calibration slope reflects the average effects of the
predictors in the model and was estimated in a logistic regression model with the logit of the
model predictions as the only predictor. For a perfect model, the slope is equal to 1.
The current study is part of the IMPACT project that was exempt from institutional review
board approval. The analyses were performed using SPSS Statistics (Version 17.0.2, IBM
Corporation, Somers, NY, USA) and the R software environment (Version 2.7.1, The R
Foundation for Statistical Computing, Vienna, Austria) with the Design and Hmisc
packages.
RESULTS
Datasets
The observational series included a more heterogeneous case-mix than the trial populations
(Table 2). This was illustrated by the summary measure for heterogeneity: the strictly
selected trial populations had a lower value (e.g., Pharmos: 0.58) than the observational
series (e.g., TARN: 1.75).
The distributions of the Glasgow Outcome Scale score for both the IMPACT and CRASH
development datasets were U-shaped (Figure 1). In NABIS, APOE and Pharmos, the U-
shaped outcome distribution had largely disappeared because a higher proportion of patients
had severe disability: 26% in both NABIS and APOE and 29% in Pharmos, compared to
16% in IMPACT and 15% in CRASH. This resulted in a greater proportion of patients with
unfavourable outcome. In IMPACT and CRASH the proportions of unfavourable outcome
were 48% and 47% respectively, while in NABIS this was 56%, in APOE 53% and in
Pharmos 51%.
Model performance
Discrimination—Discrimination of the different models varied between the datasets
(Table 3). For prediction of mortality, AUCs varied between 0.65 and 0.83 for the IMPACT
Core model and between 0.66 and 0.85 for the CRASH Basic model. For prediction of
unfavourable outcome, AUCs between 0.66 and 0.76 were found for the IMPACT Core
model and between 0.68 and 0.76 for the CRASH Basic model. Discrimination improved for
both the IMPACT and CRASH models with increasing complexity of the models.
Discrimination was better in the observational datasets (TARN and APOE) than in the trials,
which was largely explained by a more heterogeneous case-mix, compared to the
development population (small difference between development AUC and case-mix-
corrected AUC, Table 3). When the model was refitted in the validation data, the
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performance was similar to the performance of the externally validated original model
(small difference between external validation AUC and refitted AUC).
Calibration—The calibration slope and intercept values of the validation datasets and
models are summarized in Table 3.
In Pharmos, the calibration plots indicated some degree of miscalibration (Figure 2a and 2b).
This was also expressed in the calibration slopes, indicating differences in predictor effects
between the development and validation populations. For the IMPACT Core model the
slopes were 0.733 for mortality and 0.634 for unfavourable outcome. The CRASH Basic
model showed calibration slopes of 0.641 (mortality) and 0.645 (unfavourable outcome). In
TARN, miscalibration was less apparent in the calibration plots. Calibration slopes were
1.318 (IMPACT Core model) and 1.375 (CRASH Basic model).
With regard to calibration-in-the-large, in Pharmos, an intercept of −0.774 was found for
mortality prediction with the IMPACT Core model, indicating that the model’s predictions
were moderately higher than the observed mortality. However, prediction of unfavourable
outcome with the IMPACT Core model showed an intercept of 0.286, indicating mild
underestimation of the outcome by the model. A similar pattern was observed for the
CRASH Basic model. In TARN, the IMPACT Core model gave an intercept of 0.124 and
the CRASH Basic model of 0.110 for prediction of mortality.
Sensitivity analysis—Because of the high proportion of patients with missing data on
pupillary reactivity in the TARN data, we also performed the validation in TARN patients
with available data on pupillary reactivity (n=693). Compared to the validation with the
imputed dataset, the results were very similar for both the IMPACT Models (Core:
AUC=0.836, Slope=1.398, Intercept=1081; Extended: AUC=0.864, Slope=1.458,
Intercept=0.621) and the CRASH Models (Basic: AUC=0.850, Slope=1.333, Intercept=−
0.006; CT: AUC=0.863, Slope=1.330, Intercept=−0.031).
DISCUSSION
We confirmed the external validity of the IMPACT and CRASH prognostic models for
prediction of outcome after moderate and severe TBI in five new datasets. Importantly, these
datasets included both observational studies and clinical trials, thus permitting conclusions
on generalizability. The predictive performance of the IMPACT and CRASH models was
largely similar. Discrimination of the models varied between the different validation
populations (clinical trials vs. observational studies). Overall, the more complex models
performed better than the more simple models.
On average, performance measures did not substantially differ from those obtained in the
development populations. Although developed on 6-month mortality or unfavourable
outcome, the models also demonstrated good performance when predicting in-hospital
mortality in the TARN registry.
These conclusions support the validity of these instruments to quantify prognostic risk in
moderate and severe TBI.
Performance and generalizability of models
The CRASH and IMPACT prognostic models have been developed using state of the art
approaches on large datasets, and were externally validated reciprocally. They therefore
meet methodological quality standards (17). The IMPACT models have however been
criticized for having in part been developed on older datasets, and the CRASH models for
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having been developed exclusively on data from a clinical trial – albeit one with broad
enrollment criteria. Establishing their validity for current practice and their generalizability
to other settings is therefore important. Panczykowski et al reported good performance of
the IMPACT models (AUC: 0.76–0.83) at validation on an unselected series of 587 patients
with severe TBI admitted to a single level I trauma center (19). Honeybul et al applied the
CRASH model to a selection 147 of 1786 TBI patients who underwent a decompressive
craniectomy, to predict outcome at 18 months after injury (20). The authors noted an
overestimation of the predicted risk of unfavourable outcome, predominantly when the
predicted risk was < 80%. To our knowledge, no other validation studies on the IMPACT
and CRASH models have been performed.
Assessing performance – and its interpretation – is a complex procedure, involving multiple
levels. Many factors other than those directly related to the model itself may influence the
performance of a model. These include changing epidemiology, trauma organization,
different treatment policies, but also changes in approaches to outcome assessment. Such
external factors could influence the validity of the predictor effects (regression coefficients)
and the distribution of the predictor values in the new population (case-mix).
We observed clear effects of the case-mix on discrimination: higher AUCs were found in the
observational series (TARN and APOE) compared to the RCTs. These higher AUCs reflect
the less restrictive enrollment criteria: the greater the heterogeneity, the better the models
can distinguish patients with very low or very high predictions. We therefore strongly
discourage the indiscriminate comparisons of reported AUCs between different studies
without taking the case-mix of the development and validation population into
consideration. Use of the case-mix corrected AUC as proposed by Vergouwe et al would
appear more appropriate, as illustrated by the decrease in AUC observed in the observational
series versus the increase observed in the RCTs when calculating the case-mix-corrected
AUC (Table 3) (18).
With regard to calibration, we did observe some indication for differences in predictor
effects between the development and validation datasets. Particularly noteworthy is the
discrepancy in the calibration slopes for the Pharmos and NABIS trials: the observed
mortality is lower than predicted, whilst the number of patients with an unfavorable outcome
is substantially higher than predicted. This discrepancy could be explained by a greater
number of patients with Severe Disability than expected. Although some difference in
predictor effects may be present, we consider the different outcome distribution (Figure 1) a
more likely explanation. The main question then becomes what may have caused this
change. It may be that approaches to outcome assessment, and in particular to the
assignment of outcome categories, have changed. Pharmos and NABIS used the structured
interview as a means to better standardize outcome assignment and in the Pharmos trial a
central review of outcome assignments was performed (21). Wilson et al reported that
central assignments were generally worse, causing a shift towards more severe disability
(22). Our findings indicate that changes in the approach to assessment of the GOS, may
influence both outcome distribution and predictor effects. Clarification of this issue is
considered essential and requires a dedicated prospective study. The need for such a study is
becoming more pertinent following the recent proposals by Lu et al for yet another new
approach to assessing the extended GOS (23).
IMPACT or CRASH models?
We have often been asked the question which model should be preferred: CRASH or
IMPACT? The current validation studies do not indicate any clear preference. Both models
demonstrated comparable performance on external validation. A difference between the
IMPACT and CRASH models is the inclusion of major extracranial injury (MEI) as a
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predictor in the CRASH models. We, however, found that the added prognostic effect of
MEI in our validation series was negligible (results not shown), which may have resulted
from the case-mix of the validation datasets. In a recent meta-analysis of IMPACT, CRASH
and TARN data, we found an interaction between MEI and the clinical severity: only small
effects of MEI were noted in patients with severe TBI, whilst in mild TBI, the presence of
extracranial injury had a strong prognostic effect (24).
Perhaps the most appropriate answer to the question which model should be preferred is to
consider the setting and case-mix of the population under study. The IMPACT models were
developed on patients with moderate and severe TBI, mostly from high-income countries.
The development population for the CRASH models included also patients with mild TBI
and a substantial number of patients from low and middle-income countries. Consequently,
a preference may be expressed for the CRASH models when the population under study
includes patients with mild TBI or patients from low and middle-income countries.
Limitations
Our study has some limitations. First, due to differences in recorded predictor and outcome
variables, it was not possible to validate the original CRASH models. As described above,
we refitted the CRASH models in a selection of the CRASH trial data (GCS ≤ 12) with a
different definition of the CT variables and the GCS motor score instead of the full GCS
score. This resulted in an adapted version of the CRASH models, making them more similar
to the IMPACT models. Nevertheless, some aspects of the adapted CRASH models were
still substantially different from the IMPACT models. These differences included the
inclusion of the presence of major extracranial injury as a predictor in the CRASH models
and the inclusion of second insults (hypoxia and hypotension) as predictors to the IMPACT
Extended and Lab models. Further, the adapted CRASH models were developed to predict
early (14-day) mortality and the IMPACT models late (6-month) mortality.
It was not possible to validate all models to all new datasets, since not all required predictor
and outcome variables were recorded for each dataset. In TARN, the 6-month GOS was not
recorded as an outcome measure and only the models predicting mortality were validated on
these data. Although the outcome measure was in-hospital mortality, instead of 14-day or 6-
month mortality, both IMPACT and CRASH models performed well.
In TARN, actual CT data were not available, but derived from extensive coding of the
Abbreviated Injury Score (AIS) according to an algorithm proposed by Lesko et al. (16).
The AIS codes were, however, not only based on data of imaging studies on admission, but
also upon information of later imaging studies (CT and MRI), as well as findings during
surgery. Servadei et al have previously demonstrated that the “worst” CT may demonstrate
more abnormalities than the admission CT (25).
A further limitation was the high proportion of missing values on pupillary reactivity in the
TARN dataset (90%). Since it would be a waste of information to exclude all patients with
missing pupils (6181 patients with a total of 49496 data points), we decided to include these
patients for the validation and to statistically impute the missing values with an imputation
model. Both theoretical 15 and empirical support is growing for the use of such imputation
methods, instead of traditional complete case analyses (17). As a sensitivity analysis, we
also performed the validation in a complete case dataset of TARN, which showed very
similar results, supporting the validity of the approaches taken. The lack of availability of
some important predictors in some datasets and missing data in others illustrates the
paramount importance of standardization of data collection and coding of variables as
proposed in the common data elements initiative (26).
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CONCLUSIONS
This external validation study confirms the validity of both the IMPACT and CRASH
models in more recent datasets, with best performance in more heterogeneous observational
series. Model performance improved slightly with increasing complexity of the models, but
most information is captured in three key predictors: age, GCS motor score, and pupillary
reactivity. No relevant difference in performance was found between the IMPACT and the
CRASH models. These findings confirm generalizability of the models in new data and
support the use of the models for a wide a range of applications. These include the
classification of future TBI patient populations (especially exploiting the discriminative
ability of the models) and calculation of the baseline prognostic risk of individual patients
(requiring good calibration of the models).
It may be expected that the effects of treatment and health care organization on outcome of
individual patients change over time. This underlines the necessity of re-validation of these
prognostic models in the future, to re-confirm generalizability or to update the models on
more recent patient populations. This should become a continuing process, and highlights
the need for a prospective high quality observational study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Figure 1a. Six-month Glasgow Outcome Scale in development (IMPACT and CRASH) and
validation datasets (NABIS Hypothermia, Cerestat, APOE and Pharmos).
Figure 1b. In-hospital mortality in the TARN-TBI registry.
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Figure 2.
Figure 2a. Calibration plots for external validation of the IMPACT and CRASH models for
prediction of 6-month unfavourable outcome in the Pharmos trial data. Predicted
probabilities are on the x-axis and observed outcomes on the y-axis. The triangles indicate
the observed frequencies by quantiles of predicted probability with 95% confidence intervals
(vertical lines). The distribution of the predicted probabilities is shown at the bottom of the
graphs, separate for those with and without the outcome of interest.
Figure 2b. Calibration plots for external validation of the IMPACT and CRASH models for
prediction of mortality in the Pharmos trial data.
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Figure 3.
Calibration plots for external validation of the IMPACT and CRASH models for prediction
of mortality in the TARN TBI dataset.
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Table 1
Variables included in the IMPACT models and adapted CRASH models.
IMPACT Models: predicting unfavourable outcome and mortality at six months
Core Model Extended Model Lab Model
Age Core Model variables + Extended Model variables +
GCS motor score CT Classification Glucose
Pupillary reactivity EDH Hemoglobin
tSAH
Hypoxia
Hypotension
CRASH Models: predicting unfavourable outcome at six months and mortality at 14 days
Basic Model CT Model
Age Basic Model variables+
GCS motor score CT Classification
Pupillary reactivity tSAH
Major extracranial injury
IMPACT= International Mission on Prognosis and Analysis of Clinical Trials in TBI; GCS= Glasgow Coma Scale; CT= computed tomography;
EDH= epidural hematoma; tSAH= traumatic subarachnoid hemorrhage; CRASH= Corticosteroid Randomisation After Significant Head Injury
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